A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: The combination of capivasertib and abiraterone acetate had an acceptable tolerability profile consistent with the known profile of each agent. These data support further evaluation of capivasertib and abiraterone acetate in patients with advanced prostate cancer.PMID:36572571 | DOI:10.1016/j.clgc.2022.11.017
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Neal Shore Bego ña Mellado Satish Shah Ralph Hauke Dan Costin Nabil Adra Marie Cullberg Carlos Fernandez Teruel Thomas Morris Source Type: research
More News: Abiraterone Acetate | Anemia | Cancer | Cancer & Oncology | Oral Cancer | Pain | Prednisone | Prostate Cancer | Study | Toxicology | Urology & Nephrology